How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?

In patients with NSCLC, treatment decisions for uncommon EGFR mutations differ significantly from common mutations like exon 19 deletion and L858R. Treatment is personalized based on the specific type of uncommon mutation, which varies in its sensitivity to EGFR tyrosine kinase inhibitors (TKIs).

Fo...